| Home Health Vna Of Nh | |
| 10 Corporate Dr Ste 2203, Bedford, New Hampshire 3110 | |
| (603) 854-5657 | |
| Not Available |
| Name | Home Health Vna Of Nh |
|---|---|
| Location | 10 Corporate Dr Ste 2203, Bedford, New Hampshire |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 307096 |
| Ownership Type | Voluntary Non-profit - Private |
| Service Area Zip Codes | 3038, 3051, 3076, 3079 |
| NPI Number | 1619433984 |
| Organization Name | HOME HEALTH VNA INC |
| Doing Business As | HOME HEALTH VNA-NH |
| Address | 10 Corporate Dr Ste 2203, Bedford, NH 03110 |
| Phone Number | 603-854-5657 |
News Archive
Researchers in Denmark and the Netherlands have conducted a study showing that sex and gender are not being adequately considered in clinical trials investigating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the coronavirus disease 2019 (COVID-19) pandemic.
Too many major sports arenas in Europe do not have adequate equipment and procedures in place to save the lives of spectators who suffer heart attacks while watching a sporting event, according to new research published online today (Wednesday 3 March) in the European Heart Journal.
Unwashed hands in England's hospitals are contributing to the spread of meticillin-resistant Staphylococcus aureus (MRSA) and will continue unless healthcare professionals are taught to assess risk, reveals new research.
Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.
› Verified 2 days ago
| Quality Rating: | Not Available* |
| * This measure currently does not have data or provider has been certified/recertified for less than 6 months. | |
News Archive
Researchers in Denmark and the Netherlands have conducted a study showing that sex and gender are not being adequately considered in clinical trials investigating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the coronavirus disease 2019 (COVID-19) pandemic.
Too many major sports arenas in Europe do not have adequate equipment and procedures in place to save the lives of spectators who suffer heart attacks while watching a sporting event, according to new research published online today (Wednesday 3 March) in the European Heart Journal.
Unwashed hands in England's hospitals are contributing to the spread of meticillin-resistant Staphylococcus aureus (MRSA) and will continue unless healthcare professionals are taught to assess risk, reveals new research.
Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.
› Verified 2 days ago
News Archive
Researchers in Denmark and the Netherlands have conducted a study showing that sex and gender are not being adequately considered in clinical trials investigating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the coronavirus disease 2019 (COVID-19) pandemic.
Too many major sports arenas in Europe do not have adequate equipment and procedures in place to save the lives of spectators who suffer heart attacks while watching a sporting event, according to new research published online today (Wednesday 3 March) in the European Heart Journal.
Unwashed hands in England's hospitals are contributing to the spread of meticillin-resistant Staphylococcus aureus (MRSA) and will continue unless healthcare professionals are taught to assess risk, reveals new research.
Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.
› Verified 2 days ago
Home Health Vna Of Nh Location: 10 Corporate Dr Ste 2203, Bedford, New Hampshire 3110 Ratings: NA Phone: (603) 854-5657 |